UZH-Logo

Maintenance Infos

Browse by Creators - Zurich Open Repository and Archive

Navigate back| Up a level
Export as
Number of items: 10.

Papassotiropoulos, A; Lambert, J C; Wavrant-De Vrièze, F; Wollmer, M A; von der Kammer, H; Streffer, J R; Maddalena, A; Huynh, K D; Wolleb, S; Lütjohann, D; Schneider, B; Thal, D R; Grimaldi, L M E; Tsolaki, M; Kapaki, E; Ravid, R; Konietzko, U; Hegi, T; Pasch, T; Jung, H; Braak, H; Amouyel, P; Rogaev, E I; Hardy, J; Hock, C; Nitsch, R M (2005). Cholesterol 25-hydroxylase on chromosome 10q is a susceptibility gene for sporadic Alzheimer's disease. Neurodegenerative Diseases, 2(5):233-241.

Papassotiropoulos, A; Maddalena, A; Gretener, D; Nitsch, R M; Hock, C (2004). Cerebrospinal fluid biomarkers for the diagnosis of Alzheimer's disease. In: Hyman, B T; Demonet, L F; Christen, Y. The Living Brain and Alzheimer’s Disease. Berlin [etc.]: Springer Verlag , 17-24.

Hock, C; Konietzko, U; Streffer, J R; Tracy, J; Signorell, A; Müller-Tillmanns, B; Lemke, U; Henke, K; Moritz, E; Garcia, E; Wollmer, M A; Umbricht, D; de Quervain, D J F; Hofmann, M; Maddalena, A; Papassotiropoulos, A; Nitsch, R M (2003). Antibodies against beta-amyloid slow cognitive decline in Alzheimer's disease. Neuron, 38(4):547-554.

Maddalena, A; Papassotiropoulos, A; Müller-Tillmanns, B; Jung, H H; Hegi, T; Nitsch, R M; Hock, C (2003). Biochemical diagnosis of Alzheimer disease by measuring the cerebrospinal fluid ratio of phosphorylated tau protein to beta-amyloid peptide42. Archives of Neurology, 60(9):1202-1206.

Papassotiropoulos, A; Streffer, J R; Tsolaki, M; Schmid, S; Thal, D; Nicosia, F; Iakovidou, V; Maddalena, A; Lütjohann, D; Ghebremedhin, E; Hegi, T; Pasch, T; Träxler, M; Brühl, A; Benussi, L; Binetti, G; Braak, H; Nitsch, R M; Hock, C (2003). Increased brain beta-amyloid load, phosphorylated tau, and risk of Alzheimer disease associated with an intronic CYP46 polymorphism. Archives of Neurology, 60(1):29-35.

Hock, C; Maddalena, A; Raschig, A; Müller-Spahn, F; Eschweiler, G; Hager, K; Heuser, I; Hampel, H; Müller-Thomsen, T; Oertel, W; Wienrich, M; Signorell, A; Gonzalez-Agosti, C; Nitsch, R M (2003). Treatment with the selective muscarinic m1 agonist talsaclidine decreases cerebrospinal fluid levels of A beta 42 in patients with Alzheimer's disease. Amyloid, 10(1):1-6.

Wollmer, M A; Papassotiropoulos, A; Streffer, J R; Grimaldi, L M E; Kapaki, E; Salani, G; Paraskevas, G P; Maddalena, A; de Quervain, D; Bieber, C; Umbricht, D; Lemke, U; Bosshardt, S; Degonda, N; Henke, K; Hegi, T; Jung, H H; Pasch, T; Hock, C; Nitsch, R M (2002). Genetic polymorphisms and cerebrospinal fluid levels of tissue inhibitor of metalloproteinases 1 in sporadic Alzheimer's disease. Psychiatric Genetics, 12(3):155-160.

Theurillat, J P; Hainfellner, J A; Maddalena, A; Weissenberger, J; Aguzzi, A (1999). Early induction of angiogenetic signals in gliomas of GFAP-v-src transgenic mice. American Journal of Pathology, 154(2):581-590.

Rovigatti, U; Afanasieva, T A; Brandner, S; Hainfellner, J A; Kiess, M; Maddalena, A; Malin, G; Rülicke, T; Steinbach, J; Weissenberger, J; Aguzzi, A (1998). Transgenic mice as research tools in neurocarcinogenesis. Journal of Neurovirology, 4(2):159-174.

Aguzzi, A; Maddalena, A; Brandner, S; Klein, M (1997). [Molecular pathogenesis of spongiform encephalopathy.]. Pathologica, 89(5):481-490.

This list was generated on Tue Jul 25 11:53:36 2017 CEST.